Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults

Background—Although cyclooxygenase-2 inhibitors (coxibs) were developed to cause less gastrointestinal hemorrhage than nonselective nonsteroidal antiinflammatory drugs (NSAIDs), there has been concern about their cardiovascular safety. We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit. Methods and Results—We conducted a matched case-control study of 54 475 patients 65 years of age or older who received their medications through 2 state-sponsored pharmaceutical benefits programs in the United States. All healthcare use encounters were examined to identify hospitalizations for AMI. Each of the 10 895 cases of AMI was matched to 4 controls on the basis of age, gender, and the month of index date. We constructed matched logistic regression models including indicators for patient demographics, healthcare use, medication use, and cardiovascular risk factors to assess the relative risk of AMI in patients who used rofecoxib compared with persons taking no NSAID, taking celecoxib, or taking NSAIDs. Current use of rofecoxib was associated with an elevated relative risk of AMI compared with celecoxib (odds ratio [OR], 1.24; 95% CI, 1.05 to 1.46; P = 0.011) and with no NSAID (OR, 1.14; 95% CI, 1.00 to 1.31; P = 0.054). The adjusted relative risk of AMI was also elevated in dose-specific comparisons: rofecoxib ≤25 mg versus celecoxib ≤200 mg (OR, 1.21; 95% CI, 1.01 to 1.44; P = 0.036) and rofecoxib >25 mg versus celecoxib >200 mg (OR, 1.70; 95% CI, 1.07 to 2.71; P = 0.026). The adjusted relative risks of AMI associated with rofecoxib use of 1 to 30 days (OR, 1.40; 95% CI, 1.12 to 1.75; P = 0.005) and 31 to 90 days (OR, 1.38; 95% CI, 1.11 to 1.72; P = 0.003) were higher than >90 days (OR, 0.96; 95% CI, 0.72 to 1.25; P = 0.8) compared with celecoxib use of similar duration. Celecoxib was not associated with an increased relative risk of AMI in these comparisons. Conclusions—In this study, current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use. Dosages of rofecoxib >25 mg were associated with a higher risk than dosages ≤25 mg. The risk was elevated in the first 90 days of use but not thereafter.

[1]  L. Title,et al.  Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[2]  F. Ruschitzka,et al.  Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced Hypertension , 2003, Circulation.

[3]  JoAnn E. Manson,et al.  Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.

[4]  Peter C Austin,et al.  Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. , 2003, Archives of internal medicine.

[5]  F. Ruschitzka,et al.  Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease , 2003, Circulation.

[6]  W. White,et al.  Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. , 2002, The American journal of cardiology.

[7]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[8]  R. Bolli,et al.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. , 2002, Cardiovascular research.

[9]  H. Guess,et al.  Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. , 2002, Archives of internal medicine.

[10]  E. Rahme,et al.  Association between naproxen use and protection against acute myocardial infarction. , 2002, Archives of internal medicine.

[11]  Daniel H Solomon,et al.  Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. , 2002, Archives of internal medicine.

[12]  T. Grosser,et al.  Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.

[13]  J. Morrow,et al.  Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice , 2002, Circulation.

[14]  W. White,et al.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. , 2002, The American journal of cardiology.

[15]  R. Sperling,et al.  Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). , 2002, The American journal of cardiology.

[16]  M. Province,et al.  Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). , 2001, The American journal of cardiology.

[17]  R. Sperling,et al.  Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib , 2001, Circulation.

[18]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[19]  F. Cipollone,et al.  Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.

[20]  S A Rich,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[21]  P. Lipsky,et al.  Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. , 2000, Archives of internal medicine.

[22]  Purnima Chawla,et al.  Implications of a health lifestyle and medication analysis for improving hypertension control. , 2000, Archives of internal medicine.

[23]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[24]  R. Kington,et al.  DataBase: Research and Evaluation Results , 1997, American journal of public health.

[25]  M. Gimbrone,et al.  Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Krumholz,et al.  Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. , 1995, JAMA.

[27]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[28]  G. Adler,et al.  A Profile of the Medicare Current Beneficiary Survey , 1994, Health care financing review.

[29]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[30]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.